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Although pharmacological therapy and allergen avoidance are effective means of 
managing allergic disease, allergen-specific immunotherapy is able to treat not only 
the symptoms, but also the underlying causes of the disease. Sublingual immuno-
therapy (SLIT) has been shown to be effective in patients with allergic diseases. It 
has demonstrated long-term clinical benefits and shown the potential to modify the 
course of allergic disease in children with rhinitis, conjunctivitis, and asthma. The 
precise mechanisms of SLIT remain unclear, but antigen-presenting cells in the oral 
mucosa may induce regulatory T-cells that suppress the allergic immune response 
by increasing production of interleukin-10. SLIT has also been shown to increase 
allergen-specific IgG antibodies that antagonize and block the allergic response. SLIT 
was well tolerated in all reported, double-blinded, placebo-controlled, randomized 
trials. SLIT is an ideal means of treating the pediatric population because of its excel-
lent safety and good compliance. However, the optimal dose and duration of SLIT 
require further investigation.
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1. Introduction
The prevalence of IgE-mediated hypersensitivity 
has increased over the past few decades. Related 
clinical diseases range from trivial rhinitis to life-
threatening asthma.1 Although pharmacological 
therapy and allergen avoidance are effective means 
of managing allergic disease, allergen-specific im-
munotherapy is able to treat not only the symptoms, 
but also the underlying causes of the disease.2 An 
early study in 1961 reported the use of subcutane-
ous immunotherapy (SCIT) in children,3 but subse-
quent studies found that this administration route 
was associated with the risk of severe adverse 
events. Safer routes of administration have there-
fore been investigated and developed. Oral and 
bronchial administration have been abandoned be-
cause controlled trials failed to demonstrate clini-
cal efficacy and safety. Local nasal immunotherapy, 
although effective and safe, is limited because it 
requires a particular administration technique, and 
is only effective against rhinitis.4 Sublingual immu-
notherapy (SLIT) is considered to be a better treat-
ment modality associated with less severe systemic 
adverse effects and better compliance, compared 
with conventional SCIT.
In 1993, the European Academy of Allergy and 
Clinical Immunology proposed that the safety and 
Sublingual immunotherapy in children 45
efficacy of SLIT should be investigated. In 1998, 
the World Health Organization suggested that SLIT 
could be used in adults with allergic rhinitis, but 
decided that there was still insufficient evidence 
to justify its use in children. In 2001, an Allergic 
Rhinitis and its Impact on Asthma (ARIA) document 
reported that SLIT had been evaluated in studies 
of allergic rhinitis induced by certain pollens and 
mites. In 2003, the American Academy of Allergy, 
Asthma & Immunology (AAAAI)-American College 
of Allergy, Asthma and Immunology (ACAAI) clinical 
guidelines concluded that “further studies are 
needed to confirm the efficacy and safety of opti-
mal dose sublingual-swallow immunotherapy in 
children and adults”. The AAAAI and ACAAI formed 
a joint task force with the purpose of providing a 
comprehensive, updated report on SLIT for the North 
American allergy community. There have been two 
studies of SLIT in Taiwan. A multi-center, double-
blind, randomized and placebo-controlled study by 
Niu et al5 showed that SLIT administered at ultra-
high doses in a rushed schedule to mite-sensitive 
asthmatic children improved asthma scores and 
lung function tests. Another double-blind, random-
ized and placebo-controlled study by Leu et al6 
also revealed that SLIT was clinically effective in 
reducing symptoms and medication use in asth-
matic children sensitized to mites. Mite-specific 
IgG4 significantly increased after treatment with 
SLIT in this study. Both these SLIT studies in Taiwan 
demonstrated good patient tolerance and safety. 
This review explores the efficacy, mechanisms, 
safety, compliance, and recent advances in SLIT 
for the treatment of children.
2. Efficacy of SLIT in Children
The results of many double-blind, placebo-controlled, 
randomized trials of SLIT treatment in children, 
using a wide range of allergen doses, have been 
published (Table 1). The use of SLIT for the treat-
ment of allergic rhinitis caused by mites, or by grass, 
birch, or Parietaria pollen, was examined in a meta-
analysis including 22 trials and 979 patients, which 
showed significant efficacy compared with pla-
cebo.7 However, studies in this meta-analysis that 
only involved children with allergic rhinitis showed 
no significant reduction in symptoms or medica-
tion scores. However, it may not be possible to 
reach a reliable conclusion based on these studies 
because of the small numbers of participants; there 
were only five studies involving 218 children.7 
Another meta-analysis of the use of SLIT to treat 
pediatric patients with allergic rhinitis included 
10 studies and 577 patients, and demonstrated the 
efficacy of SLIT by reductions in symptoms and 
medication use after immunotherapy. It also showed 
that SLIT administered for more than 18 months 
using pollen extracts was more effective than SLIT 
courses administered for less than 18 months and 
using mites.8 
There have been fewer studies of SLIT for asthma 
treatment than for the treatment of allergic rhi-
nitis, and the effects of SLIT on asthma remain 
controversial. A meta-analysis of SLIT for asthma, 
including 25 studies and 1,706 patients, revealed a 
significant reduction in asthma severity based on the 
use of asthma medications, lung function, and bron-
chial provocation, but did not show improvements 
Table 1  Double-blind, placebo-controlled trials of the efficacy of sublingual immunotherapy for the treatment of 
children since 2000
First author Year Reference 
Age range No. of patients 
Allergen Duration Disease Effects
   (yr) Active/Placebo
Caffarelli 2000 41 4−14 24/20 Grass 3 mo R/A +
Pajno 2000 32 8−15 12/12 Mite 2 yr A +
Bahceciler 2001 42 7−15 8/7 Mite 6 mo R/A +
Ippoliti 2003 43 5−12 47/39 Mite 6 mo R/A +
Marcucci 2003 44 4−16 13/11 Mite 1 yr R/C/A +
Pajno 2003 14 8−14 15/15 Parietaria 13 mo R/C/A +
Wuthrich 2003 45 6−13 11/11 Grass 2 yr R/A +
Bufe 2004 46 6−13 68/74 Grass 3 yr R/A +
Novembre 2004 17 5−14 48/49 Grass 3 yr R/A +
Rolinck-Werninghaus 2004 47 3−14 39/38 Grass 3 yr R/C +
Niu 2006  5 6−12 49/48 Mite 6 mo A +
Lue 2006  6 6−12 10/10 Mite 6 mo A +
Valovirta 2006 48 6−14 59/29 Mixture 18 mo R/C +
Ibanez 2007 10 5−12 45/15 Grass 1 mo R/C/A +
Pham-Thi 2007 13 5−15 55/56 Mite 18 mo A −
R = rhinitis; C = conjucntivitis; A = asthma.
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in asthma symptoms.9 More recent studies have 
demonstrated the efficacy and safety of SLIT in 
children with grass pollen seasonal allergic rhino-
conjunctivitis and asthma.10 One study also found 
that SLIT produced a greater reduction in allergic 
symptoms and airway inflammation in children with 
asthma who were allergic to house dust mites com-
pared with pharmacotherapy.11 SLIT also improved 
sub jects’ forced vital capacity, forced expiratory vol-
ume in first second, and peak expiratory flow, as 
compared with baseline, in mite-sensitive asth-
matic children.5 As an adjunct to pharmacother-
apy, 3 years of SLIT combined with pharmacotherapy 
resulted in reductions in both the duration and 
dose of inhaled corticosteroids and allowed the 
successful discontinuation of inhaled corticoster-
oids, along with improvements in lung functions.12 
Nonetheless, Pham-Thi et al demonstrated that al-
though SLIT resulted in a significant reduction in 
the allergic response to house dust mites by reduc-
ing skin sensitivity as well as specific IgE and IgG 
antibodies, it did not provide any additional benefit 
in children with mild-moderate asthma who were 
already optimally controlled by pharmacotherapy 
and mite avoidance.13 Pajno et al also reported that 
SLIT had no additional benefit in seasonal asthmatic 
children allergic to Parietaria pollen who had been 
treated with inhaled fluticasone propionate, al-
though SLIT could reduce the early and late skin re-
sponses and significantly improve the non-bronchial 
symptoms.14
Allergic rhinitis, conjunctivitis and asthma are 
considered to be different manifestations of atopy. 
Immunotherapy for allergic rhinitis may prevent the 
development of asthma. Over the years, increasing 
amounts of evidence have shown that SCIT can pre-
vent the progression of rhinitis to asthma, and can 
reduce the severity of asthma.15 A 10-year follow-
up study recently showed that a 3-year course of 
SCIT produced long-term clinical effects and had 
the potential to prevent the development of sea-
sonal and perennial asthma in children.16 Regarding 
SLIT, a study of children with rhinoconjuctivitis 
demonstrated that after 3 years of co-seasonal SLIT 
therapy with grass pollen allergen, symptoms of 
seasonal allergic rhinitis and the development of 
seasonal asthma were reduced.17 In addition to its 
ability to modify the natural history of allergic dis-
ease and prevent the onset of new sensitization, 
immunotherapy also maintains its clinical efficacy 
3−5 years after its discontinuation.18 In children with 
asthma due to house dust mites, SLIT reduced the 
incidence of asthma at the end of treatment, and 
continued to have an effect even 4−5 years after 
treatment discontinuation.19 The clinical improve-
ment was strengthened by the use of long-term 
(2−3 years) SLIT.20 
3. Mechanisms of SLIT
Most studies of SLIT have examined its efficacy and 
safety. However, the exact mechanisms behind SLIT 
are still under investigation. Contact of the aller-
gen with the oral mucosa is a key to the success of 
SLIT. A systemic immune response, as well as a local 
immune reaction, is involved. The Langerhans-like 
dendritic cells capture the allergen in the oral cav-
ity. They subsequently mature and migrate to the 
proximal lymph nodes, where blocking IgG anti-
bodies are produced and suppressor T lymphocytes 
are induced.21 A specific function for these cells has 
been suggested because of their high expression of 
Fcε receptor type I, major histocompatibility com-
plex class I and II, and some costimulatory molecules 
(CD40, CD80/B7.1, and CD86/B7.2), which pro-
foundly differ from those of skin Langerhans cells.22
An increase in IgG production is one mechanism 
of immunotherapy. Antigen-specific IgG antibodies 
can antagonize and block the allergic response re-
sulting from the production of IgE against the harm-
less antigen. The balance between IgE and IgG, 
especially IgG4 subtype, is crucial for the success 
of allergen-specific immunotherapy. SLIT has been 
shown to increase allergen-specific IgG4 levels in 
children with asthma due to house dust mites,23 
and with allergic rhinitis,24 and these findings were 
further confirmed in a meta-analysis of SLIT stud-
ies.7 A decrease in the IgE/IgG4 ratio has been 
observed in several SLIT studies in children with 
asthma caused by house dust mites25 and with al-
lergic rhinitis,24 though a recent study reported a 
lack of detectable alteration in immune response.26 
Further studies are needed to clarify the mechanism 
of blocking antibodies in SLIT.
Allergic patients are known to usually mount 
strong allergen-specific T-cell responses involving 
T helper 2 (Th2) cells.27 In healthy individuals, reg-
ulatory T cells represent the dominant allergen-
specific subset (Figure 1). Regulatory T cells secrete 
interleukin (IL)-10 (type 1 regulatory T cells; Tr1) 
and transforming growth factor (TGF)-β (Th3 cells), 
which directly or indirectly suppress allergic inflam-
mation. The purpose of allergen-specific immuno-
therapy is to restore tolerance by shifting T-cell 
responses from Th2- to regulatory T-cell responses. 
Studies have shown that SCIT can induced regula-
tory T cells to downregulate both Th1 and Th2 re-
sponses.28 To date, however, there is less evidence 
regarding the impact of SLIT on T-cell responses. 
SLIT failed to induce the proliferation of dendritic 
cells or T lymphocytes in the epithelium or lamina 
propria of the oral mucosa in children with rhino-
conjunctivitis and asthma due to olive pollen.29 SLIT 
had no significant effect on T-cell functions, such 
as cytokine production, in children with seasonal 
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allergic rhinoconjunctivitis to grass pollen.26 A re-
cent preliminary study showed that IL-10 increased 
in vitro stimulation by Dermatophagoides, as well 
as recall antigens from Candida albicans and phy-
tohaemagglutinin, in peripheral blood mononuclear 
cells from house dust mite-allergic patients after 
3 years of SLIT.30 T-cell proliferation induced in vitro 
by C. albicans, Parietaria, and grasses was signifi-
cantly reduced in patients treated with SLIT for 
house dust mite allergy.31 Further investigations are 
needed to confirm the roles of regulatory T cells, 
IL-10, and TGF-β in patients treated with SLIT. 
4. Dosing, Frequency and Duration of SLIT
Published controlled trials of SLIT have used vari-
able doses of allergens. Compared with SCIT, SLIT 
requires 50−100 times more allergen to reach similar 
levels of efficacy.2 However, it has been suggested 
that the use of cumulative doses up to a threshold 
is important for successful SLIT, and these may not 
differ greatly from the doses used in SCIT.32 SLIT 
may be started at the full maintenance dose, with-
out the gradual increase in dose that is usual for 
SCIT. The only agent that is currently commercially 
available for SLIT is extract of grass pollen, and the 
standard dose consists of a single sublingual tablet, 
taken once daily. Treatment is most effective when 
initiated at least 2 months before the start of the 
pollen season.33 Studies of SLIT in children have 
used variable cumulative doses measured in differ-
ent units. The duration ranged from 3 months to 
3 years. To date, there are no experimental data on 
the optimal duration of SLIT, and the optimal main-
tenance dose and administration schedule require 
further investigation.
5. Safety and Compliance of SLIT
The excellent safety of allergens administrated by 
the sublingual route, as shown by numerous stud-
ies in past years, makes SLIT a suitable method for 
treating allergies in the pediatric population.34 
SCIT induced more systemic and anaphylactic reac-
tions in children with asthma than in children with 
rhinitis, and the severity differed between differ-
ent allergens.35 These disadvantages of the subcu-
taneous route confine the use of SCIT to specialized 
medical centers. By contrast, all reported, double-
blind, placebo-controlled, randomized trials of SLIT 
have shown it to be well tolerated. SLIT has been 
used in both rhinitis and asthma patients, with no 
occurrence of anaphylactic reactions,23,36 and its 
safety has also been confirmed in clinical trials in 
children with rhinitis and asthma.36 The most fre-
quent adverse effects were local (oral pruritus, 
throat irritation or mouth edema) or gastrointestinal 
(nausea, vomiting, diarrhea or abdominal pain). The 
overall incidence of side effects varied from 3−18% 
of patients.19 In a recent extensive review of the 
literature, 17 serious adverse events, mainly asthma, 
and two anaphylactic events, were reported.37 No 
life-threatening or fatal events have been reported 
in any study.
Compliance with SLIT is generally good, and only 
a small number of patients have been withdrawn 
because of worsening symptoms. In the pediatric 
population using SLIT, incidents of poor compliance 
were mostly due to parents who discontinued the 
treatment because the symptoms had improved.17 
Compliance is an important factor for increasing 
the efficacy and decreasing the occurrence of side 
effects.38 Therefore, educational and socioeconomic 
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Figure 1 Possible mechanism of sublingual immuno-
therapy (SLIT). SLIT deals with allergy by inducing long-
term immune deviation towards regulatory T cells 
responses. During an allergic immune response, Th2 cells 
produce interleukins that promote IgE production by 
B cells, and activate mast cells, eosinophils and basophils 
that release inflammatory mediators. Regulatory T cells 
suppress the activity of Th2 cells and promote IgG and IgA 
production, rather than IgE. The main cytokines in volved 
appear to be interleukin-10 and transforming growth 
factor-β. IL-10 = interleukin-10; TGF-β = transforming growth 
factor-β.
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status should be taken into consideration when 
administering SLIT. 
6. Future Developments in SLIT
In the majority of cases, SLIT is administered in the 
form of drops, with only occasional use of tablets.7 
The change from drops to tablets could provide a 
further advance in standardizing SLIT dosing and 
vaccine development. The convenience of taking 
tablets may enhance compliance, which is a key to 
increasing efficacy and reducing side effects.
Sublingual vaccines are currently based on aque-
ous biological extracts from natural allergen sources, 
and have demonstrated both safety and clinical ef-
ficacy. With recent advances in the understanding 
of oral mucosal immunity and new proteomic tech-
niques, second-generation sublingual vaccines based 
on recombinant allergens are under development. 
These recombinant allergens are molecularly de-
fined, and are easier and more reproducible and 
traceable to produce. The strategy of using recom-
binant allergens represents an alternative ap-
proach directed at eliciting an IgG response and 
activating T cells, while reducing the capacity to bind 
allergen-specific IgE, thereby reducing the risk of 
IgE-dependent side effects such as mast cell de-
granulation.39 Tests of SCIT using subcutaneous re-
combinant vaccines have yielded promising results.40 
However, there have been no clinical trials of re-
combinant allergen sublingual vaccines. The use of 
recombinant allergens may permit an individualized 
approach to diagnosis and therapy in the future.
Vaccine preparation strategies also consider the 
use of biological or synthetic adjuvants to improve 
allergen presentation, and new allergen formula-
tions other than drops or tablets (e.g., powder, bio-
films or mucoadhesive tablets) to prolong mucosal 
contact and facilitate allergen capture by immune 
cells. These approaches could help to enhance SLIT 
efficacy, reduce allergen dosage, and simplify ad-
ministration schedules. 
7. Conclusions
The use of SLIT provides an attractive option, espe-
cially in the pediatric population, for outpatient, 
home-based and self-administered therapy. It is 
preferable to the use of SCIT, which is limited to 
medical centers and must be administered by health 
care professionals. Good compliance with SLIT may 
result in better chances of success for immuno-
therapy. The long-term clinical efficacy of SLIT has 
been demonstrated in children with allergic rhini-
tis and asthma, and the progression of atopy was 
reduced. SLIT is particularly appropriate for children 
because of its safety, tolerable adverse effects, and 
good compliance. Although the exact immunological 
mechanisms by which SLIT induces tolerance against 
allergens remain unclear, current understanding, 
particularly of the role of regulatory T cells, may 
enable the development of improved treatment 
strategies. Various forms of sublingual vaccine in-
volving the use of adjuvants, new allergen formu-
lations, and recombinant allergens, are currently 
under evaluation. Advances in these fields can pro-
vide information leading to more rational and safer 
approaches to doses and optimal duration in order 
to achieve the best long-term effects that could, 
in the future, prevent and cure allergic disease.
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